Korro Bio, Inc. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Korro Bio, Inc. (Nasdaq: KRRO) on May 13, 2024. The filing reports a significant corporate event under Item 8.01 (Other Events) regarding a change in executive leadership.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
Effective May 13, 2024, Dr. Kemi Olugemo, M.D., FAAN, joined Korro Bio, Inc. as its Chief Medical Officer. This appointment represents a material change in the company's senior management team.
Management Commentary and Background
Dr. Olugemo brings extensive experience in clinical development for rare and common diseases. Her prior roles include:
- Vice President of Global Clinical Development at Ultragenyx Pharmaceutical Inc. (Dec 2022 – May 2024).
- Head of Clinical Development at Laronde, Inc. (now Sail Bio, Inc.) (Nov 2021 – Dec 2022).
- Executive Director of Clinical Development at Ionis Pharmaceuticals Inc. (Nov 2019 – Nov 2021).
- Senior Director of Global Therapeutic Area Head, Neuroscience at Parexel International Corp (June 2014 – Nov 2019).
Dr. Olugemo holds an M.D. from the University of Maryland School of Medicine and completed a Fellowship in Neuroimmunology & Multiple Sclerosis.
Investor Verification Checklist
- Confirm the effective start date of Dr. Olugemo's tenure as Chief Medical Officer.
- Review the company's clinical pipeline to assess how Dr. Olugemo's background in neuroimmunology and rare diseases aligns with current therapeutic programs.
- Check for any concurrent filings regarding compensation agreements or equity grants associated with this appointment.